Ensysce Receives FDA Guidance on Opioid With Overdose Protection
Ensysce Biosciences Receives FDA Guidance For PF614-MPAR Program
The meeting focused on the Company's non-clinical program for the combination product that is designed for the treatment of severe pain. The FDA provided helpful feedback and advice on non-clinical st
Ensysce Biosciences Announces Successful Meeting With FDA for PF614-MPAR, a Next Generation Opioid With Overdose Protection
Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, is providing an update following its recent meeting with the Food and Drug Administration (FDA) regarding its second product, a 'Next Generation' opioid analgesic with overdose protection, PF614-MPAR.
Ensysce Biosciences Reports Promising PF614 Study Results
Ensysce Biosciences Secures Funding and Expands Shareholder Value
Ensysce Biosciences Exercises Rights to Buy Shares at a Lower Price